<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566761</url>
  </required_header>
  <id_info>
    <org_study_id>MECRVO</org_study_id>
    <nct_id>NCT00566761</nct_id>
  </id_info>
  <brief_title>Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO</brief_title>
  <acronym>MECROV</acronym>
  <official_title>Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of macular edema secondary to central retinal vein occlusion is more effective with
      combined therapy of bevacizumab and triamcinolone than bevacizumab alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of two groups with different treatment with registrations of outcome in BCVA and
      complications
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">March 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Best corrected visual acuity and macular edema measured with OCT</measure>
    <time_frame>Follow up to 3 , 6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Report treatment complications</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Macular Edema</condition>
  <condition>Central Retinal Vein Occlusion</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab and triamcinolone</intervention_name>
    <description>three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Macular edema secondary to central retinal vein occlusion

          -  BCVA worse than 20/40

          -  Central macular &gt;250 mc with OCT

        Exclusion Criteria:

          -  Diabetic retinopathy or other retinopathy

          -  Media opacity that does not allow following

          -  steroid responder

          -  diagnosed glaucoma or IOP &gt; 21 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Gonzalez-Mijares, Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>APEC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugo Quiroz-Mercado, Retinologyst</last_name>
    <role>Study Director</role>
    <affiliation>APEC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Manuel Jimenez Sierra, Retinologyst</last_name>
    <role>Study Chair</role>
    <affiliation>APEC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MA Martinez-Castellanos, Physician</last_name>
    <role>Study Chair</role>
    <affiliation>APEC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Octavio Burgos Vejar, Physician</last_name>
    <role>Study Chair</role>
    <affiliation>APEC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raul Velez-Montoya, Physician</last_name>
    <role>Study Chair</role>
    <affiliation>APEC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ma de Lourdes Lopez Ramos, Physician</last_name>
    <role>Study Chair</role>
    <affiliation>APEC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Omar Honerlager, preresident</last_name>
    <role>Study Chair</role>
    <affiliation>APEC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carmen Conzalez-Mijares, Physician</last_name>
    <phone>5517638245</phone>
    <email>cacegomi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asociacion Para Evitar la Ceguera en Mexico</name>
      <address>
        <city>Mexico city</city>
        <state>Coyoacan</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Retina Department</last_name>
      <phone>5510841400</phone>
      <phone_ext>1171</phone_ext>
      <email>retinamex@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2007</study_first_submitted>
  <study_first_submitted_qc>November 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2007</study_first_posted>
  <last_update_submitted>November 30, 2007</last_update_submitted>
  <last_update_submitted_qc>November 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2007</last_update_posted>
  <responsible_party>
    <name_title>Carmen Cecilia Gonzalez Mijares</name_title>
    <organization>Asociación para Evitar la Ceguera en Mexico IAP</organization>
  </responsible_party>
  <keyword>Macular edema</keyword>
  <keyword>central retinal vein occlusion</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>triamcinolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

